Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura H Tang

Showing results (41-50 of 172) with videos related to

Pageof 18
Sort By:
Annals of Surgery|April 24, 2009
Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancerInderpal S Sarkaria, Nabil P Rizk, Manjit S Bains, et al.
Molecular Cell|June 15, 2010
Negative regulation of tumor suppressor p53 by microRNA miR-504Wenwei Hu, Chang S Chan, Rui Wu, et al.
Oncotarget|April 23, 2016
Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5Tanupriya Contractor, Shinta Kobayashi, Edaise da Silva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
BRCA germline mutations in Jewish patients with pancreatic adenocarcinomaCristina R Ferrone, Douglas A Levine, Laura H Tang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 13, 2012
Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinomaNabil P Rizk, Elliot L Servais, Laura H Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2007
Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?Cristina R Ferrone, Laura H Tang, James Tomlinson, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 1, 2014
Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signalingSimon Schimmack, Andrew Taylor, Ben Lawrence, et al.
Archives of Pathology & Laboratory Medicine|October 3, 2014
Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens From Patients With Adenocarcinoma of the Stomach or Esophagogastric JunctionAngela N Bartley, Jessi Christ, Patrick L Fitzgibbons, et al.
Cancer Research|August 2, 2017
Oncogenic KRAS and p53 Loss Drive Gastric Tumorigenesis in Mice That Can Be Attenuated by E-Cadherin ExpressionJacob E Till, Changhwan Yoon, Bang-Jin Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2015
Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine CarcinomasLaura H Tang, Brian R Untch, Diane L Reidy, et al.
Pageof 18

Showing results (41-50 of 172) with videos related to

Sort By:
Pageof 18
Annals of Surgery|April 24, 2009
Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancerInderpal S Sarkaria, Nabil P Rizk, Manjit S Bains, et al.
Molecular Cell|June 15, 2010
Negative regulation of tumor suppressor p53 by microRNA miR-504Wenwei Hu, Chang S Chan, Rui Wu, et al.
Oncotarget|April 23, 2016
Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5Tanupriya Contractor, Shinta Kobayashi, Edaise da Silva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
BRCA germline mutations in Jewish patients with pancreatic adenocarcinomaCristina R Ferrone, Douglas A Levine, Laura H Tang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 13, 2012
Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinomaNabil P Rizk, Elliot L Servais, Laura H Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2007
Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?Cristina R Ferrone, Laura H Tang, James Tomlinson, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 1, 2014
Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signalingSimon Schimmack, Andrew Taylor, Ben Lawrence, et al.
Archives of Pathology & Laboratory Medicine|October 3, 2014
Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens From Patients With Adenocarcinoma of the Stomach or Esophagogastric JunctionAngela N Bartley, Jessi Christ, Patrick L Fitzgibbons, et al.
Cancer Research|August 2, 2017
Oncogenic KRAS and p53 Loss Drive Gastric Tumorigenesis in Mice That Can Be Attenuated by E-Cadherin ExpressionJacob E Till, Changhwan Yoon, Bang-Jin Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2015
Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine CarcinomasLaura H Tang, Brian R Untch, Diane L Reidy, et al.
Pageof 18